Martigues

Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.

Hidradenitis Suppurativa HS is a skin condition that causes painful bumps, abscesses, scars, and tunnels in areas where the skin rubs together. This condition may start when hair follicles become damaged, triggering the immune system and allowing bacteria to worsen the symptoms. Researchers are evaluating the safety, effectiveness, and tolerance of a drug called zasocitinib in adults with moderate to severe HS compared with a placebo in this Phase 2 clinical trial. Participants will be randomly assigned to receive either zasocitinib or a placebo for the first 16 weeks in a double-blind period. After this, all participants will receive zasocitinib for an additional 36 weeks in an open-label period. The placebo capsules look like zasocitinib but contain no medicine. Treatment dosing involves a specific dose of zasocitinib labeled as Dose A. During the study, participants will visit the clinic 12 times for assessments. Researchers will monitor the percentage of participants achieving a 75 reduction in HS symptoms at week 16 as the primary outcome. They will also track safety through adverse events and other measures throughout the 56 weeks of treatment. Participants will undergo evaluations including clinical exams, questionnaires, and safety tests to understand treatment effects and tolerability.

Vitiligo is a long-term autoimmune condition where the bodys immune system attacks skin cells that produce pigment, causing patches without color. This study is focused on adults with nonsegmental vitiligo, where patches appear symmetrically on both sides of the body. Researchers aim to learn how safe and tolerable the drug zasocitinib is, and how well it works for this condition. Participants will be randomly assigned to receive different doses of zasocitinib capsules or a placebo. Those initially on placebo will switch to a medium or high dose of zasocitinib after about six months. The treatment period lasts up to 52 weeks with several dosage groups including low, medium, and high doses of zasocitinib. During the study, participants will visit the clinic 11 times for assessments. Researchers will measure improvements using the Facial Vitiligo Area Scoring Index F-VASI and the Total Vitiligo Area Scoring Index T-VASI. Safety, tolerability, and effectiveness will be monitored throughout the study, with the main outcome assessed at week 24. Participants will be closely followed to track treatment responses and any side effects.

Researchers are studying the safety and effects of Abrocitinib for adults with moderate to severe chronic atopic dermatitis, a long-lasting skin condition causing inflammation, redness, and irritation. The study focuses on real-life use of Abrocitinib to understand its impact and safety in this patient group. Participants must be over 18 years old without medical conditions that prevent using Abrocitinib. All participants will take Abrocitinib tablets once daily and may continue using medicated topical treatments alongside the study drug. The study lasts 24 months, during which participants will visit the clinic approximately five times, roughly once every 4 to 6 months. The study collects observational data to describe the effects and safety of Abrocitinib over this period. Participants will undergo assessments including skin evaluations using tools like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Researchers will monitor symptoms such as itch severity and sleep quality, along with treatment adherence and any side effects. Safety and effectiveness will be reviewed regularly throughout the study and at its end, with ongoing observation of treatment patterns and patient-reported outcomes.

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

Researchers are studying post-thrombotic syndrome PTS, a common long-term complication of deep vein thrombosis DVT that affects quality of life and treatment costs. The study aims to evaluate whether the volume of thrombosis DVT burden, measured by the Venous Volumetric Index VVI using ultrasound, can predict the risk and severity of PTS at six months. This could help improve prediction and management strategies for patients with DVT. This multicenter prospective study enrolls patients with a first acute episode of symptomatic DVT in the lower limbs. Participants undergo assessments including ultrasound scans to calculate the VVI score and clinical evaluations using the Villalta score for PTS symptoms. Blood samples for inflammation and coagulation markers are collected at several visits, and quality of life questionnaires are completed at three and six months. Follow-up visits occur at one week, one month, three months, and six months. Participants will be evaluated through symptom assessments, ultrasound imaging, blood tests, and questionnaires over six months. The primary outcome is the presence of moderate to severe PTS at six months. Researchers will monitor thrombosis burden and other prognostic factors at each visit to understand their relationship with PTS development. The study concludes after the six-month visit with no further follow-up planned.

Psoriasis is a chronic inflammatory condition influenced by genetic and environmental factors, often leading to recurrent skin flare-ups. This trial evaluates the effectiveness of bimekizumab, a drug, compared to topical corticosteroids in managing psoriasis symptoms. The study aims to determine if early intervention with bimekizumab can delay the chronic inflammation typically seen in psoriasis over a 24-week period. Participants will be randomly assigned to one of two groups one group receives 320mg of bimekizumab at weeks 0, 4, 8, and 12, while the other uses clobetasol ointment daily for up to 4 weeks until the lesion clears. Afterward, clobetasol will be applied twice weekly until week 16, then stopped. No active treatment is given between weeks 16 and 24. From week 24 to 96, patients who experience flare-ups may use clobetasol continuously but will be classified as non-responders for main analysis. If psoriasis worsens to moderate or severe, participants leave the study for standard care. During the study, various assessments and sample collections will monitor the disease and treatment effects. Researchers will measure psoriasis activity using clinical tools at 24 weeks, focusing on skin condition and quality of life. Patients must attend all study visits and follow procedures, with the total participation period extending to up to 96 weeks depending on flare-ups and treatment response.

Benign prostatic hyperplasia BPH, also known as prostate adenoma, is a common non-cancerous enlargement of the prostate affecting mainly men over 40 years old. This condition often causes lower urinary tract symptoms LUTS such as difficulty starting urination, frequent urination, especially at night, and a decrease in urine flow. Researchers are evaluating the safety and effectiveness of a high-intensity focused ultrasound HIFU treatment specifically targeted to reduce prostate volume and improve urinary symptoms in men with BPH. The study uses HIFU, a technique that applies focused ultrasonic waves to heat and destroy targeted prostate tissue precisely without invasive surgery or radiation. This treatment is delivered endorectally using a specialized probe to target the affected prostate areas. The study observes patients at 3, 6, 12, 18, and 36 months after treatment to assess safety, symptom improvement, prostate size reduction, urinary flow changes, and sexual function. Participants will undergo various assessments including MRI scans, urinary flow measurements, and questionnaires on urinary symptoms, quality of life, and erectile and ejaculatory function. Researchers will monitor adverse events and treatment effects over 36 months. The study aims to gather detailed information about treatment safety and effectiveness through regular follow-up visits and evaluations.

This research aims to evaluate patient satisfaction after a multidisciplinary complex assessment conducted in a Day Hospital for adults diagnosed with cancer and scheduled to receive injectable anticancer treatment. The study focuses on understanding how patients feel about this coordinated care approach involving multiple healthcare professionals and its impact on overall quality of care in oncology. The assessment involves consultations with a pharmacist, dietitian, psychologist, social worker, and supportive care providers to identify patient-specific needs and improve care coordination early in the treatment process. All patients undergoing this assessment are invited to complete an anonymous satisfaction questionnaire as part of routine care. Participants will complete the satisfaction questionnaire after their Day Hospital assessment, covering quality of care, interactions with healthcare providers, and organization of services. Researchers will analyze overall satisfaction, satisfaction by specialty, factors influencing satisfaction, and the Net Promoter Score. Results aim to enhance patient-centered oncology care and guide continuous quality improvement until the study ends in April 2029.

Researchers are evaluating whether a new imaging method called high resolution micro-ultrasound microUS, approved by the FDA and Health Canada, is as effective as the current standard imaging technique, multiparametric MRI, for screening the prostate gland. This phase 3 clinical trial aims to identify which imaging approach better guides the decision to proceed with a prostate biopsy in men aged 50 to 70 who are at risk for prostate cancer. Participants will be randomly assigned to one of two groups to receive either the standard prostate multiparametric MRI or the experimental microUS imaging. These imaging procedures will be compared to assess their ability to detect prostate abnormalities. The study is conducted at multiple centers internationally, and both imaging methods are non-invasive diagnostic devices. Men enrolled in the study will be followed for one year after their imaging test to monitor the detection of clinically significant prostate cancer. Researchers will collect data on imaging results and biopsy decisions to evaluate each methods effectiveness. Participants will undergo standard clinical assessments, and study visits will be scheduled to track outcomes during the follow-up period.